Safety and Efficacy of AAV9. hMCOLN1co For Patients With Mucolipidosis Type IV
Safety and Efficacy of AAV9. hMCOLN1co For Patients With Mucolipidosis Type IV
Enrolling by invitation · NCT07398872 · Registry updated 2026-02-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of AAV9. hMCOLN1co For Patients With Mucolipidosis Type IV | Bone Diseases, Metabolic, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lysosomal Storage Diseases, Nervous System, Nutritional and Metabolic Diseases, bone disorder, brain disorder, central nervous system disorder, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, mucolipidosis, musculoskeletal system disorder, nervous system disorder | Enrolling by invitation | Phase 1 | 2026-02-10 | NCT07398872 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The Children's Hospital of Zhejiang University School of Medicine | 74 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital Zhejiang University School of Medicine | Hangzhou | China | 7 |